Accounts Payable

12 Months Ended

Dec. 31, 2012

Accounts Payable Disclosure [Abstract]

Accounts Payable

5. Accounts Payable

As of December 31, 2012, Current Liabilities included accounts payable of $57,000 comprised primarily of amounts owed to the Company’s drug contract manufacturer totaling $6,300, approximately $15,760 to the company providing clinical operations management for Bio-Path’s clinical trial, $11,980 to the Company’s attorneys and auditors and $14,940 for business wire and public filing expense; and accounts payable – related party of $8,582 comprised of siRNA patent expenses incurred during 2012. These amounts were subsequently paid in the first quarter of 2013. As of December 31, 2011, Current Liabilities included accounts payable $121,540 and accounts payable – related party of $67,971, which amounts were subsequently paid in 2012.